Clinical Trial: NCT04962126
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Olivia Newton-John Cancer Research Institute |
| Information Provided By: | Olivia Newton-John Cancer Research Institute |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma.
The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.
Official Title
Conditions
Intervention / Treatment
- Drug: Obinutuzumab 25 MG/1 ML Intravenous Solution
- Drug: Atezolizumab 1200 MG/40mL Intravenous Solution
- Radiation: 4 Gy in 2 fractions
Other Study ID Numbers
- FLUORO
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Olivia Newton-John Cancer Research Institute |
| Information Provided By: | Olivia Newton-John Cancer Research Institute |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma.
The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.
Official Title
Conditions
Intervention / Treatment
- Drug: Obinutuzumab 25 MG/1 ML Intravenous Solution
- Drug: Atezolizumab 1200 MG/40mL Intravenous Solution
- Radiation: 4 Gy in 2 fractions
Other Study ID Numbers
- FLUORO